Osteoarthritis
Conditions
Keywords
Osteoarthritis, oral salmon calcitonin, treatment, efficacy,, tolerability
Brief summary
The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee
Interventions
0.8mg SMC021, twice daily
0.8mg Placebo, twice daily
Sponsors
Study design
Eligibility
Inclusion criteria
* Medical history and symptoms of knee osteoarthritis
Exclusion criteria
* Any other disease or medication affecting the bone or cartilage. * Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial. Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months | Change from baseline to 24 months | The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24. |
| Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index | Change from baseline to 24 months | WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Questionnaire to Assess Function and Physical Activity | From baseline to months 1, 6, 12 and 24 | Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992): I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities. III. Able to perform usual self-care activities, but limited in vocational and avocational activities. IV. Limited ability to perform usual self-care activities, vocational and avocational activities. Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific. |
| Questionnaire to Assess Stiffness in the Signal Knee. | Baseline to month 24 | WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness). Patients were instructed not to take analgesics for 3 days prior to the WOMAC test. |
| Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | From baseline to 24 months | The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24. |
| Questionnaire to Assess Pain | Baseline, month 1, month 6, month 12, month 24 | Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled No Pain and 100 equaled Worst Pain Imaginable. Patients were instructed not to take analgesics for 3 days prior to the VAS. |
| Questionnaire to Assess Health-related Quality of Life | From baseline to month 24 | Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years. The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state). The change from baseline in the EQ-5D VAS was calculated. |
| Knee Disease Progression Assessed by MRI | From baseline to month 12 and month 24 | Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site. |
Countries
Belgium, Canada, Czechia, Denmark, Hong Kong, Poland, Romania, Spain, United Kingdom, United States
Participant flow
Recruitment details
Patients were enrolled at 18 centers in 10 countries: 6 centers in the US, 1 center in the UK, 1 center in Spain,1 center in the Czech Republic, 3 centers in Denmark, 1 center in Hong Kong, 2 centers in Poland, 1 center in Romania, 1 center in Belgium and 1 center in Canada. First patient randomized: 1 Aug 08 Last patient visit: 10 May 2011
Participants by arm
| Arm | Count |
|---|---|
| SMC021 Oral Calcitonin 0.8 mg SMC021 Oral Calcitonin twice daily | 521 |
| SMC021 Placebo 1 SMC021 Placebo tablet twice daily | 509 |
| Total | 1,030 |
Baseline characteristics
| Characteristic | SMC021 Oral Calcitonin | SMC021 Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 229 Participants | 221 Participants | 450 Participants |
| Age, Categorical Between 18 and 65 years | 292 Participants | 288 Participants | 580 Participants |
| Age, Continuous | 64.4 years STANDARD_DEVIATION 7 | 64.2 years STANDARD_DEVIATION 6.8 | 64.3 years STANDARD_DEVIATION 6.9 |
| Region of Enrollment Belgium | 7 participants | 7 participants | 14 participants |
| Region of Enrollment Canada | 11 participants | 8 participants | 19 participants |
| Region of Enrollment Czech Republic | 36 participants | 35 participants | 71 participants |
| Region of Enrollment Denmark | 263 participants | 264 participants | 527 participants |
| Region of Enrollment Hong Kong | 72 participants | 72 participants | 144 participants |
| Region of Enrollment Poland | 67 participants | 66 participants | 133 participants |
| Region of Enrollment Romania | 9 participants | 9 participants | 18 participants |
| Region of Enrollment Spain | 4 participants | 2 participants | 6 participants |
| Region of Enrollment United Kingdom | 26 participants | 25 participants | 51 participants |
| Region of Enrollment United States | 26 participants | 21 participants | 47 participants |
| Sex: Female, Male Female | 321 Participants | 305 Participants | 626 Participants |
| Sex: Female, Male Male | 200 Participants | 204 Participants | 404 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 474 / 520 | 459 / 508 |
| serious Total, serious adverse events | 77 / 520 | 80 / 508 |
Outcome results
Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months
The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.
Time frame: Change from baseline to 24 months
Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 2 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SMC021 Oral Calcitonin | Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months | -0.32 mm | Standard Deviation 0.693 |
| SMC021 Placebo | Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months | -0.40 mm | Standard Deviation 0.768 |
Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index
WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).
Time frame: Change from baseline to 24 months
Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 2 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SMC021 Oral Calcitonin | Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index | -80.6 Units on a scale | Standard Deviation 112.22 |
| SMC021 Placebo | Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index | -87.9 Units on a scale | Standard Deviation 116.25 |
Bone & Cartilage Metabolism Biochemical Marker Change (Percentage).
The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24.
Time frame: From baseline to 24 months
Population: The number of participants analysed for these outcomes were a total of 150 subjects from the intent-to-treat (ITT) population evenly distributed across sites, all with completed baseline as well as all follow-up visits.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SMC021 Oral Calcitonin | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | Serum CTX-I (ng/mL) | 50.6 percentage of change | Standard Deviation 83.74 |
| SMC021 Oral Calcitonin | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | Serum Osteocalcin (ng/mL) | 3.6 percentage of change | Standard Deviation 37.42 |
| SMC021 Oral Calcitonin | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | 24-h urine CTX-I/creatinine (µg/mmol) | 9.8 percentage of change | Standard Deviation 85.95 |
| SMC021 Oral Calcitonin | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | 24-h urine CTX-II/creatinine (ng/mmol) | 2.6 percentage of change | Standard Deviation 63.13 |
| SMC021 Placebo | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | 24-h urine CTX-II/creatinine (ng/mmol) | 2.3 percentage of change | Standard Deviation 51.07 |
| SMC021 Placebo | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | Serum CTX-I (ng/mL) | 40.6 percentage of change | Standard Deviation 45.52 |
| SMC021 Placebo | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | 24-h urine CTX-I/creatinine (µg/mmol) | 7.2 percentage of change | Standard Deviation 44.36 |
| SMC021 Placebo | Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). | Serum Osteocalcin (ng/mL) | 3.9 percentage of change | Standard Deviation 26.32 |
Knee Disease Progression Assessed by MRI
Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.
Time frame: From baseline to month 12 and month 24
Population: Subset of patients from the sites in Ballerup (Denmark), Czech Republic and Romania
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SMC021 Oral Calcitonin | Knee Disease Progression Assessed by MRI | Cartilage Volume Month 12 | 3.4 percentage of change | Standard Deviation 9.11 |
| SMC021 Oral Calcitonin | Knee Disease Progression Assessed by MRI | Cartilage Volume Month 24 | 2.6 percentage of change | Standard Deviation 10.18 |
| SMC021 Oral Calcitonin | Knee Disease Progression Assessed by MRI | Cartilage Thickness Month 12 | 4.7 percentage of change | Standard Deviation 10.64 |
| SMC021 Oral Calcitonin | Knee Disease Progression Assessed by MRI | Cartilage Thickness Month 24 | 4.5 percentage of change | Standard Deviation 10.78 |
| SMC021 Placebo | Knee Disease Progression Assessed by MRI | Cartilage Thickness Month 24 | 4.1 percentage of change | Standard Deviation 8.67 |
| SMC021 Placebo | Knee Disease Progression Assessed by MRI | Cartilage Volume Month 12 | 3.0 percentage of change | Standard Deviation 13.16 |
| SMC021 Placebo | Knee Disease Progression Assessed by MRI | Cartilage Thickness Month 12 | 4.7 percentage of change | Standard Deviation 8.24 |
| SMC021 Placebo | Knee Disease Progression Assessed by MRI | Cartilage Volume Month 24 | 3.5 percentage of change | Standard Deviation 12.73 |
Questionnaire to Assess Function and Physical Activity
Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992): I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities. III. Able to perform usual self-care activities, but limited in vocational and avocational activities. IV. Limited ability to perform usual self-care activities, vocational and avocational activities. Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific.
Time frame: From baseline to months 1, 6, 12 and 24
Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SMC021 Oral Calcitonin | Questionnaire to Assess Function and Physical Activity | Month 1 | -4.8 percentage of change | Standard Deviation 44.89 |
| SMC021 Oral Calcitonin | Questionnaire to Assess Function and Physical Activity | Month 6 | -22.6 percentage of change | Standard Deviation 49.03 |
| SMC021 Oral Calcitonin | Questionnaire to Assess Function and Physical Activity | Month 12 | -28.0 percentage of change | Standard Deviation 53.97 |
| SMC021 Oral Calcitonin | Questionnaire to Assess Function and Physical Activity | Month 24 | -30.3 percentage of change | Standard Deviation 77.51 |
| SMC021 Placebo | Questionnaire to Assess Function and Physical Activity | Month 12 | -28.4 percentage of change | Standard Deviation 59.79 |
| SMC021 Placebo | Questionnaire to Assess Function and Physical Activity | Month 1 | -1.9 percentage of change | Standard Deviation 131.2 |
| SMC021 Placebo | Questionnaire to Assess Function and Physical Activity | Month 24 | -25.1 percentage of change | Standard Deviation 143.05 |
| SMC021 Placebo | Questionnaire to Assess Function and Physical Activity | Month 6 | -17.9 percentage of change | Standard Deviation 64.15 |
Questionnaire to Assess Health-related Quality of Life
Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years. The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state). The change from baseline in the EQ-5D VAS was calculated.
Time frame: From baseline to month 24
Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SMC021 Oral Calcitonin | Questionnaire to Assess Health-related Quality of Life | 13.70 percentage of change | Standard Deviation 38.763 |
| SMC021 Placebo | Questionnaire to Assess Health-related Quality of Life | 11.82 percentage of change | Standard Deviation 40.645 |
Questionnaire to Assess Pain
Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled No Pain and 100 equaled Worst Pain Imaginable. Patients were instructed not to take analgesics for 3 days prior to the VAS.
Time frame: Baseline, month 1, month 6, month 12, month 24
Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SMC021 Oral Calcitonin | Questionnaire to Assess Pain | Month 1 | -6.7 percentage of change | Standard Deviation 49.5 |
| SMC021 Oral Calcitonin | Questionnaire to Assess Pain | Month 6 | -26.9 percentage of change | Standard Deviation 51.73 |
| SMC021 Oral Calcitonin | Questionnaire to Assess Pain | Month 12 | -31.0 percentage of change | Standard Deviation 68.05 |
| SMC021 Oral Calcitonin | Questionnaire to Assess Pain | Month 24 | -35.1 percentage of change | Standard Deviation 91.63 |
| SMC021 Placebo | Questionnaire to Assess Pain | Month 24 | -37.1 percentage of change | Standard Deviation 77.55 |
| SMC021 Placebo | Questionnaire to Assess Pain | Month 1 | -9.1 percentage of change | Standard Deviation 45.26 |
| SMC021 Placebo | Questionnaire to Assess Pain | Month 12 | -34.6 percentage of change | Standard Deviation 61.3 |
| SMC021 Placebo | Questionnaire to Assess Pain | Month 6 | -26.9 percentage of change | Standard Deviation 50.43 |
Questionnaire to Assess Stiffness in the Signal Knee.
WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness). Patients were instructed not to take analgesics for 3 days prior to the WOMAC test.
Time frame: Baseline to month 24
Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SMC021 Oral Calcitonin | Questionnaire to Assess Stiffness in the Signal Knee. | -26.1 percentage of change | Standard Deviation 90.88 |
| SMC021 Placebo | Questionnaire to Assess Stiffness in the Signal Knee. | -20.3 percentage of change | Standard Deviation 179.22 |